Halozyme Therapeutics: Steady Growth In A Challenged Market
Halozyme Therapeutics sees strong Q4 2024 growth, driven by ENHANZE platform royalties. Click here to find out why HALO stock ...
Fierce Pharma2d
Roche settles UPenn suit alleging patent infringement by Herceptin, 3 other breast cancer meds
Some three years after the University of Pennsylvania claimed four of Roche’s breast cancer meds infringed its intellectual ...
NHS England4d
Thousands of NHS patients to benefit from ‘take at home’ multiple sclerosis tablet in European first
Thousands of NHS patients in England with multiple sclerosis (MS) are set to benefit from a life-changing ‘take at home’ tablet, as the NHS becomes the first healthcare system in Europe to roll it out ...
Hosted on MSN25d
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q4 2024 Earnings Call Transcript
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q4 2024 Earnings Call Transcript February 18, 2025 Halozyme Therapeutics, Inc. beats earnings expectations. Reported EPS is $1.26, expectations were $1.17 ...
Yahoo Finance26d
HALO's Q4 Earnings Beat, Higher Royalties Drive Revenue Growth
The top-line growth was primarily driven by higher royalty payments from Roche RHHBY for Phesgo and J&J JNJ for subcutaneous Darzalex (daratumumab) as well as an increase in milestone revenues ...